The therapy also incorporates a proprietary co‑stimulatory engineering design meant to overcome immune resistance often present in solid tumors, thereby improving T cell durability and response potential even in hostile tumor microenvironments. Pan Cancer T’s pipeline extends beyond TNBC. The company is developing TCR‑T therapies for a broad range of solid cancers, including cancers of the bladder, ovary, colorectum, prostate, skin, oesophagus, lung, and brain.